Start of final bull run ahead of 9th November FDA announcement of Heplisav . $28 price projection. Final buy opportunity at $20
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
